2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Nandita Nadig; Adarsh Bhimraj; Kelly Cawcutt; Kathleen Chiotos; Amy L. Dzierba; Arthur Y. Kim; Greg S. Martin; Jeffrey C. Pearson; Amy Hirsch Shumaker; Lindsey R. Baden; Roger Bedimo; Vincent Chi Chung Cheng; Kara W. Chew; Eric S. Daar; David V. Glidden; Erica J. Hardy; Steven Johnson; Jonathan Z. Li; Christine Macbrayne; Mari M. Nakamura; Laura Riley; Robert W. Shafer; Shmuel Shoham; Pablo Tebas; Phyllis C. Tien; Jennifer Loveless; Yngve Falck-Ytter; Rebecca L. Morgan; Rajesh T. Gandhi

doi:10.1093/cid/ciaf235

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Nandita Nadig
, Adarsh Bhimraj
, Kelly Cawcutt
, Kathleen Chiotos
, Amy L. Dzierba
, Arthur Y. Kim
, Greg S. Martin
, Jeffrey C. Pearson
, Amy Hirsch Shumaker
, Lindsey R. Baden
, Roger Bedimo
, Vincent Chi Chung Cheng
, Kara W. Chew
, Eric S. Daar
, David V. Glidden
, Erica J. Hardy
, Steven Johnson
, Jonathan Z. Li
, Christine Macbrayne
, Mari M. Nakamura

Laura Riley, Robert W. Shafer, Shmuel Shoham, Pablo Tebas, Phyllis C. Tien, Jennifer Loveless, Yngve Falck-Ytter, Rebecca L. Morgan, Rajesh T. Gandhi

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

Original language	English (US)
Pages (from-to)	i13-i16
Journal	Clinical Infectious Diseases
Volume	81
DOIs	https://doi.org/10.1093/cid/ciaf235
State	Published - Oct 15 2025

Keywords

COVID-19
SARS-CoV-2
guideline
monoclonal antibody
vilobelimab

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciaf235

Cite this

Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., Macbrayne, C., ... Gandhi, R. T. (2025). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clinical Infectious Diseases, 81, i13-i16. https://doi.org/10.1093/cid/ciaf235

Nadig, N, Bhimraj, A, Cawcutt, K, Chiotos, K, Dzierba, AL, Kim, AY, Martin, GS, Pearson, JC, Shumaker, AH, Baden, LR, Bedimo, R, Cheng, VCC, Chew, KW, Daar, ES, Glidden, DV, Hardy, EJ, Johnson, S, Li, JZ, Macbrayne, C, Nakamura, MM, Riley, L, Shafer, RW, Shoham, S, Tebas, P, Tien, PC, Loveless, J, Falck-Ytter, Y, Morgan, RL & Gandhi, RT 2025, '2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab', Clinical Infectious Diseases, vol. 81, pp. i13-i16. https://doi.org/10.1093/cid/ciaf235

@article{5cf158509bf84b5ab4ca7cea51690bc3,

title = "2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab",

abstract = "This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.",

keywords = "COVID-19, SARS-CoV-2, guideline, monoclonal antibody, vilobelimab",

author = "Nandita Nadig and Adarsh Bhimraj and Kelly Cawcutt and Kathleen Chiotos and Dzierba, \{Amy L.\} and Kim, \{Arthur Y.\} and Martin, \{Greg S.\} and Pearson, \{Jeffrey C.\} and Shumaker, \{Amy Hirsch\} and Baden, \{Lindsey R.\} and Roger Bedimo and Cheng, \{Vincent Chi Chung\} and Chew, \{Kara W.\} and Daar, \{Eric S.\} and Glidden, \{David V.\} and Hardy, \{Erica J.\} and Steven Johnson and Li, \{Jonathan Z.\} and Christine Macbrayne and Nakamura, \{Mari M.\} and Laura Riley and Shafer, \{Robert W.\} and Shmuel Shoham and Pablo Tebas and Tien, \{Phyllis C.\} and Jennifer Loveless and Yngve Falck-Ytter and Morgan, \{Rebecca L.\} and Gandhi, \{Rajesh T.\}",

year = "2025",

month = oct,

day = "15",

doi = "10.1093/cid/ciaf235",

language = "English (US)",

volume = "81",

pages = "i13--i16",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19

T2 - Vilobelimab

AU - Nadig, Nandita

AU - Bhimraj, Adarsh

AU - Cawcutt, Kelly

AU - Chiotos, Kathleen

AU - Dzierba, Amy L.

AU - Kim, Arthur Y.

AU - Martin, Greg S.

AU - Pearson, Jeffrey C.

AU - Shumaker, Amy Hirsch

AU - Baden, Lindsey R.

AU - Bedimo, Roger

AU - Cheng, Vincent Chi Chung

AU - Chew, Kara W.

AU - Daar, Eric S.

AU - Glidden, David V.

AU - Hardy, Erica J.

AU - Johnson, Steven

AU - Li, Jonathan Z.

AU - Macbrayne, Christine

AU - Nakamura, Mari M.

AU - Riley, Laura

AU - Shafer, Robert W.

AU - Shoham, Shmuel

AU - Tebas, Pablo

AU - Tien, Phyllis C.

AU - Loveless, Jennifer

AU - Falck-Ytter, Yngve

AU - Morgan, Rebecca L.

AU - Gandhi, Rajesh T.

PY - 2025/10/15

Y1 - 2025/10/15

N2 - This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

AB - This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

KW - COVID-19

KW - SARS-CoV-2

KW - guideline

KW - monoclonal antibody

KW - vilobelimab

UR - https://www.scopus.com/pages/publications/105018647082

UR - https://www.scopus.com/pages/publications/105018647082#tab=citedBy

U2 - 10.1093/cid/ciaf235

DO - 10.1093/cid/ciaf235

M3 - Article

C2 - 40402009

AN - SCOPUS:105018647082

SN - 1058-4838

VL - 81

SP - i13-i16

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this